Overview

This trial is active, not recruiting.

Condition congestive heart failure
Sponsor Hadassah Medical Organization
Start date August 2008
End date December 2009
Trial size 80 participants
Trial identifier NCT00782782, 366-28.12.07

Summary

Congestive Heart failure (CHF) is asociated with changes in cardiac function and vascular responses. The aim of this study is to characterize these differences. Our hypothesis is, that there are differences in vascular responses between healthy subjects and patients with CHF.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective

Primary Outcomes

Measure
vascular sensitivity (ED50) and response (Emax) to dexmedetomidine, phenylephrine, isoproterenol and terbutaline
time frame: 3 weeks

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Patients with congestive heart failure NYHA I-II - Stable clinical condition Exclusion Criteria: - Resting systolic blood pressure < 100 - Resting heart rate < 50 - Hypersensitivity to dexmedetomidine, phenylephrine, isoproterenol, terbutaline

Additional Information

Official title Effect of Medications on Vascular Response in Patients With CHF and in Healthy Subjects
Principal investigator Mordechai Muszkat
Trial information was received from ClinicalTrials.gov and was last updated in October 2008.
Information provided to ClinicalTrials.gov by Hadassah Medical Organization.